{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:39:18Z","timestamp":1772138358869,"version":"3.50.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100010724","name":"Health Systems Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010724","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Center of Excellence in Clinical Virology"},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007693","name":"King Chulalongkorn Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011057","name":"National Center for Genetic Engineering and Biotechnology","doi-asserted-by":"publisher","award":["P2051613"],"award-info":[{"award-number":["P2051613"]}],"id":[{"id":"10.13039\/501100011057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) against SARS-CoV-2 is implemented worldwide. However, waning immunity and breakthrough infections have been observed. Therefore, we hypothesized that the heterologous booster might improve the protection against the delta and omicron variants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 224 individuals who completed the 2-dose CoronaVac for 6 months were included. We studied reactogenicity and immunogenicity after a heterologous booster with the inactivated vaccine (BBIBP), the viral vector vaccine (AZD1222), and the messenger ribonucleic acid (mRNA) vaccine (both BNT162B2 and mRNA-1273). We also determined immunogenicity at 3- and 6-month boosting intervals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The solicited adverse events were mild to moderate and well tolerated. Total receptor binding domain (RBD) immunoglobulin (Ig), anti-RBD IgG, focus reduction neutralization test (FRNT50) against delta and omicron variants, and T-cell response were highest in the mRNA-1273 group followed by the BNT162b2, AZD1222, and BBIBP groups, respectively. We also witnessed a higher total Ig anti-RBD in the long-interval than in the short-interval group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>All 4 booster vaccines significantly increased binding and neutralizing antibodies in individuals immunized with 2 doses of CoronaVac. The present evidence may benefit vaccine strategies to thwart variants of concern, including the omicron variant.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiac092","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T07:08:14Z","timestamp":1646723294000},"page":"1372-1381","source":"Crossref","is-referenced-by-count":44,"title":["Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination"],"prefix":"10.1093","volume":"226","author":[{"given":"Suvichada","family":"Assawakosri","sequence":"first","affiliation":[{"name":"Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"},{"name":"Osteoarthritis and Musculoskeleton Research Unit, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sitthichai","family":"Kanokudom","sequence":"additional","affiliation":[{"name":"Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"},{"name":"Osteoarthritis and Musculoskeleton Research Unit, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nungruthai","family":"Suntronwong","sequence":"additional","affiliation":[{"name":"Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chompoonut","family":"Auphimai","sequence":"additional","affiliation":[{"name":"Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pornjarim","family":"Nilyanimit","sequence":"additional","affiliation":[{"name":"Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preeyaporn","family":"Vichaiwattana","sequence":"additional","affiliation":[{"name":"Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanunrat","family":"Thongmee","sequence":"additional","affiliation":[{"name":"Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thaneeya","family":"Duangchinda","sequence":"additional","affiliation":[{"name":"Molecular Biology of Dengue and Flaviviruses Research Team, National Center for Genetic Engineering and Biotechnology, National Science and Development Agency, National Science and Technology Development Agency , Pathum Thani , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warangkana","family":"Chantima","sequence":"additional","affiliation":[{"name":"Division of Dengue Hemorrhagic Fever Research, Faculty of Medicine, Siriraj Hospital, Mahidol University , Bangkok , Thailand"},{"name":"Siriraj Center of Research Excellence in Dengue and Emerging Pathogens, Faculty of Medicine, Siriraj Hospital, Mahidol University , Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pattarakul","family":"Pakchotanon","sequence":"additional","affiliation":[{"name":"Molecular Biology of Dengue and Flaviviruses Research Team, National Center for Genetic Engineering and Biotechnology, National Science and Development Agency, National Science and Technology Development Agency , Pathum Thani , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donchida","family":"Srimuan","sequence":"additional","affiliation":[{"name":"Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thaksaporn","family":"Thatsanatorn","sequence":"additional","affiliation":[{"name":"Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirapa","family":"Klinfueng","sequence":"additional","affiliation":[{"name":"Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritthideach","family":"Yorsaeng","sequence":"additional","affiliation":[{"name":"Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natthinee","family":"Sudhinaraset","sequence":"additional","affiliation":[{"name":"Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasamon","family":"Wanlapakorn","sequence":"additional","affiliation":[{"name":"Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juthathip","family":"Mongkolsapaya","sequence":"additional","affiliation":[{"name":"Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford , Oxford , United Kingdom"},{"name":"Chinese Academy of Medical Science Oxford Institute, University of Oxford , Oxford , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sittisak","family":"Honsawek","sequence":"additional","affiliation":[{"name":"Osteoarthritis and Musculoskeleton Research Unit, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Poovorawan","sequence":"additional","affiliation":[{"name":"Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University , Bangkok , Thailand"},{"name":"Fellow of Royal Society of Thailand, the Royal Society of Thailand, Sanam Sueapa, Dusit , Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"2022101708574095500_CIT0001","author":"World Health Organization."},{"key":"2022101708574095500_CIT0002","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape.","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"2022101708574095500_CIT0003","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/d41586-021-02796-w","article-title":"China\u2019s COVID vaccines have been crucial - now immunity is waning.","volume":"598","author":"Mallapaty","year":"2021","journal-title":"Nature"},{"key":"2022101708574095500_CIT0004","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an Inactivated SARS-CoV-2 vaccine in Chile.","volume":"385","author":"Jara","year":"2021","journal-title":"N Engl J Med"},{"key":"2022101708574095500_CIT0005","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3822780","article-title":"Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV Study [preprint","author":"Palacios","year":"2021","journal-title":"SSRN Electron J"},{"key":"2022101708574095500_CIT0006","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"2022101708574095500_CIT0007","doi-asserted-by":"crossref","first-page":"e527","DOI":"10.1016\/S2666-5247(21)00129-4","article-title":"Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study.","volume":"2","author":"Souza","year":"2021","journal-title":"Lancet Microbe"},{"key":"2022101708574095500_CIT0008","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1473-3099(21)00681-2","article-title":"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.","volume":"22","author":"Zeng","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2022101708574095500_CIT0009","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning immunity after the BNT162b2 vaccine in Israel.","volume":"385","author":"Goldberg","year":"2021","journal-title":"N Engl J Med"},{"key":"2022101708574095500_CIT0010","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s13054-021-03662-x","article-title":"Emerging SARS-CoV-2 variants of concern and potential intervention approaches.","volume":"25","author":"Khateeb","year":"2021","journal-title":"Crit Care"},{"key":"2022101708574095500_CIT0011","doi-asserted-by":"crossref","first-page":"7967","DOI":"10.1007\/s00018-021-04008-0","article-title":"Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants.","volume":"78","author":"Gupta","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"2022101708574095500_CIT0012","doi-asserted-by":"crossref","first-page":"751778","DOI":"10.3389\/fimmu.2021.751778","article-title":"The global epidemic of the SARS-CoV-2 delta variant, key spike mutations and immune escape.","volume":"12","author":"Tian","year":"2021","journal-title":"Front Immunol"},{"key":"2022101708574095500_CIT0013","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.12.456173","article-title":"Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant [preprint","author":"Liu","year":"2021","journal-title":"bioRxiv"},{"key":"2022101708574095500_CIT0014","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S1473-3099(21)00568-5","article-title":"CoronaVac induces lower neutralising activity against variants of concern than natural infection.","volume":"21","author":"Vacharathit","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2022101708574095500_CIT0015","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.cell.2021.06.020","article-title":"Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.","volume":"184","author":"Liu","year":"2021","journal-title":"Cell"},{"key":"2022101708574095500_CIT0016","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.","volume":"602","author":"Cao","year":"2021","journal-title":"Nature"},{"key":"2022101708574095500_CIT0017","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/jmv.27524","article-title":"Characterization of the novel SARS-CoV-2 Omicron (B. 1.1. 529) variant of concern and its global perspective.","volume":"94","author":"Saxena","year":"2022","journal-title":"J Med Virol"},{"key":"2022101708574095500_CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.01.004","article-title":"Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections or vaccinees.","author":"Yang","year":"2022","journal-title":"J Infect"},{"key":"2022101708574095500_CIT0019","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/s41423-021-00767-9","article-title":"T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals.","volume":"18","author":"Jordan","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2022101708574095500_CIT0020","doi-asserted-by":"crossref","first-page":"100355","DOI":"10.1016\/j.xcrm.2021.100355","article-title":"Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals.","volume":"2","author":"Tarke","year":"2021","journal-title":"Cell Rep Med"},{"key":"2022101708574095500_CIT0021","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.02.21267198","article-title":"Homologous and heterologous vaccine boost strategies for humoral and cellular immunologic coverage of the SARS-CoV-2 omicron variant.","author":"Tan","year":"2021","journal-title":"medRxiv"},{"key":"2022101708574095500_CIT0022","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"2022101708574095500_CIT0023","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"2022101708574095500_CIT0024","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/vaccines10010086","article-title":"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine.","volume":"10","author":"Kanokudom","year":"2022","journal-title":"Vaccines"},{"key":"2022101708574095500_CIT0025","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2.","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"2022101708574095500_CIT0026","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial.","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"2022101708574095500_CIT0027","volume-title":"Comrinaty [package insert]","author":"US Food and Drug Administration."},{"key":"2022101708574095500_CIT0028","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 \u2014 preliminary report.","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"2022101708574095500_CIT0029","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.cell.2021.02.033","article-title":"Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.","volume":"184","author":"Supasa","year":"2021","journal-title":"Cell"},{"key":"2022101708574095500_CIT0030","doi-asserted-by":"crossref","first-page":"eabi6950","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody, and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals following mRNA vaccination.","volume":"6","author":"Goel","year":"2021","journal-title":"Sci Immunol"},{"key":"2022101708574095500_CIT0031","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.","volume":"399","author":"Costa Clemens","year":"2022","journal-title":"The Lancet"},{"key":"2022101708574095500_CIT0032","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-021-03696-9","article-title":"Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"2022101708574095500_CIT0033","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"2022101708574095500_CIT0034","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMc2119358","article-title":"Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection.","volume":"386","author":"Nemet","year":"2022","journal-title":"N Engl J Med"},{"key":"2022101708574095500_CIT0035","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/22221751.2021.2022440","article-title":"Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.","volume":"11","author":"Ai","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"2022101708574095500_CIT0036","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.07.21267432","article-title":"Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies [preprint","author":"Wilhelm","year":"2021","journal-title":"medRxiv"},{"key":"2022101708574095500_CIT0037","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.03.471045","article-title":"Receptor binding and escape from Beta antibody responses drive Omicron-B.1.1.529 evolution [preprint","author":"Zahradn\u00edk","year":"2021","journal-title":"bioRxiv"},{"key":"2022101708574095500_CIT0038","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"2022101708574095500_CIT0039","doi-asserted-by":"crossref","first-page":"eabj1750","DOI":"10.1126\/sciimmunol.abj1750","article-title":"SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients.","volume":"6","author":"Geers","year":"2021","journal-title":"Sci Immunol"},{"key":"2022101708574095500_CIT0040","doi-asserted-by":"crossref","first-page":"e149335","DOI":"10.1172\/JCI149335","article-title":"SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63.","volume":"131","author":"Woldemeskel","year":"2021","journal-title":"J Clin Invest"},{"key":"2022101708574095500_CIT0041","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/s41423-021-00743-3","article-title":"SARS-CoV-2-specific T cells in infection and vaccination.","volume":"18","author":"Bertoletti","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2022101708574095500_CIT0042","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2022.27.1.2101114","article-title":"Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021.","volume":"27","author":"Ireland","year":"2022","journal-title":"Euro Surveill"},{"key":"2022101708574095500_CIT0043","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4005130","article-title":"Effectiveness of homologous and heterologous booster shots for an inactivated SARS-CoV-2 vaccine: A Large-Scale Observational Study [preprint","author":"Jara","year":"2022","journal-title":"SSRN Electron J"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiac092\/43238174\/jiac092.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/8\/1372\/46542878\/jiac092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/8\/1372\/46542878\/jiac092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T04:59:41Z","timestamp":1665982781000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/226\/8\/1372\/6546425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,3,10]]},"published-print":{"date-parts":[[2022,10,17]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiac092","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.01.28.22269986","asserted-by":"object"}]},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,15]]},"published":{"date-parts":[[2022,3,10]]}}}